Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
Early Win for Gene Therapy in Rare Form of SCID 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
Black Patients Less Likely to Get Advanced Treatments for PE Also less likely for patients on Medicare and Medicaid Dec 12, 2022
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
FDA OKs First Gene Therapy for Hemophilia B Hemgenix reduced rate of annual bleeds, eliminated need for factor IX prophylaxis therapy Nov 22, 2022
Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard Europe and other countries have already followed suit Nov 01, 2022
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
How a Dedicated Bone Marrow Biopsy Clinic Eased Wait Times VA center in Cleveland got program up and running in about a month Sep 19, 2022
CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
Jane Fonda's Non-Hodgkin Lymphoma The award-winning actress opened up about her latest health news Sep 06, 2022
Bispecific Antibody Active in Heavily Treated Multiple Myeloma Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
PK Modulator Shows Promise in Thalassemia In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients Aug 17, 2022
Mandy Moore's Immune Thrombocytopenic Purpura What does it mean for the pregnant pop singer/actress? Aug 10, 2022
Experts Warn of Physical, Mental Health Effects of Extreme Heat Children, people with sickle cell disease, and outdoor workers are particularly at risk Aug 05, 2022
Pneumococcal Vax Slashed Deadly Sickle-Cell Complication in Kids Cumulative ACS reduction of 41% since implementation of 13-valent vaccine, French study finds Aug 02, 2022
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
Breast Implant-Related Lymphoma More Common Than Reported Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
Blood Viscosity Enters the Equation in COVID Mortality Its association with death may be unrelated to inflammation Jul 18, 2022
Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessment Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
